News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
CellCentric
NEWS
NEWS
Business
CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026
Pfizer-backed cancer company CellCentric will use the cash to support the launch of a pivotal myeloma trial testing its potentially first-in-class oral treatment this year.
May 6, 2026
·
1 min read
·
Gabrielle Masson
IN THE PRESS
Press Releases
CellCentric Announces Oversubscribed $220 Million Series D Financing to Advance Pivotal Trials of Inobrodib in Multiple Myeloma
May 6, 2026
·
3 min read
Press Releases
CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed or Refractory Multiple Myeloma
March 31, 2026
·
4 min read
Press Releases
CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting
December 9, 2025
·
4 min read
Business
CellCentric Ltd. Selects Sygnature Discovery (Formerly known as Sygnature Chemical Services) for Epigenetic Prostate Cancer Program
September 9, 2013
·
4 min read
Business
CellCentric Ltd. and ZoBio Enter into Partnership to Develop Lead Compounds Against Epigenetic Drug Targets
June 20, 2012
·
2 min read
Business
CellCentric Ltd. Licenses Novel Epigenetic Discovery Program to Takeda Pharmaceutical Co. Ltd. (JOBS); Deal Could be Worth Excess of $200 Million
February 23, 2010
·
3 min read
Business
CellCentric Ltd. Secures 25th Epigenetics Academic Agreement
April 21, 2009
·
2 min read
Business
CellCentric Ltd. Expands its Leadership Team
February 4, 2009
·
3 min read
Business
CellCentric Ltd. and Takeda Pharmaceutical Co. Ltd. Collaborate on Epigenetic Programme
January 6, 2009
·
2 min read
Business
Cenix BioScience GmbH and CellCentric Ltd. Second RNAi-Based Target Validation Project
July 1, 2008
·
2 min read